{'52WeekChange': 0.12727273,
 'SandP52WeekChange': 0.0644362,
 'address1': '1 Cavendish Place',
 'address2': '4th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.25,
 'askSize': 800,
 'averageDailyVolume10Day': 122425,
 'averageVolume': 316139,
 'averageVolume10days': 122425,
 'beta': 1.064597,
 'beta3Year': None,
 'bid': 3.11,
 'bidSize': 1000,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'London',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.29,
 'dayLow': 3.05,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 135028368,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 2.9801428,
 'fiftyTwoWeekHigh': 4.269,
 'fiftyTwoWeekLow': 0.69,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 22224559,
 'forwardEps': -0.19,
 'forwardPE': -16.315788,
 'fromCurrency': None,
 'fullTimeEmployees': 50,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.010629999,
 'heldPercentInstitutions': 0.15326999,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/mereobiopharma.com',
 'longBusinessSummary': 'Mereo BioPharma Group plc, a biopharmaceutical '
                        'company, acquires, develops, and commercializes '
                        'therapeutics for the treatment of oncology and rare '
                        'diseases. Its lead product candidate, etigilimab '
                        '(OMP-313M32), an antibody T-cell immunoreceptor with '
                        'Ig and ITIM domains, which is in Phase 1b clinical '
                        'trial for the treatment of tumor. The company also '
                        'develops Navicixizumab (OMP-305B83) that is in Phase '
                        '1a clinical trial for the treatment of the late line '
                        'ovarian cancer; Acumapimod (BCT-197), a p38 MAP '
                        'kinase inhibitor that has completed Phase II clinical '
                        'trial to treat acute exacerbations of chronic '
                        'obstructive pulmonary disease; and Leflutrozole '
                        '(BGS-649), an oral aromatase inhibitor for the '
                        'treatment of hypogonadotropic hypogonadism. In '
                        'addition, it develops rare disease product '
                        'candidates, including Setrusumab (BPS-804), a novel '
                        'antibody, which is in Phase IIb clinical trial for '
                        'the treatment of osteogenesis imperfect; and '
                        'Alvelestat (MPH-966), an oral small molecule that is '
                        'in Phase II clinical trial to treat Alpha-1 '
                        'antitrypsin deficiency. Mereo BioPharma Group plc was '
                        'founded in 2015 and is based in London, the United '
                        'Kingdom.',
 'longName': 'Mereo BioPharma Group plc',
 'market': 'us_market',
 'marketCap': 207251728,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_307970474',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1577750400,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.19,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '44 33 3023 7300',
 'previousClose': 3.14,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.29,
 'regularMarketDayLow': 3.05,
 'regularMarketOpen': 3.19,
 'regularMarketPreviousClose': 3.14,
 'regularMarketPrice': 3.19,
 'regularMarketVolume': 150731,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 67742800,
 'sharesPercentSharesOut': 0.010199999,
 'sharesShort': 223102,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 9692,
 'shortName': 'Mereo BioPharma Group plc',
 'shortPercentOfFloat': None,
 'shortRatio': 0.61,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'MREO',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 1.8826331,
 'volume': 150731,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.mereobiopharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'W1G 0QF'}